A Randomized, Double-blind, Placebo-controlled, Parallel Groups, Multicenter Trial Investigating the Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Women Aged 18-34 Years Undergoing Assisted Reproductive Technology
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 08 Jul 2019
Price : $35 *
At a glance
- Drugs Follitropin delta (Primary)
- Indications Female infertility
- Focus Registrational; Therapeutic Use
- Acronyms RITA-1
- Sponsors Ferring Pharmaceuticals
- 02 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 07 May 2019 Planned End Date changed from 1 Jun 2020 to 1 Jul 2021.
- 07 May 2019 Planned primary completion date changed from 1 Jun 2020 to 1 Jul 2021.